Pfizer's Oxbryta Prevents Sickling in Red Blood Cells for Pediatric SCD Patients

Ongoing stage 2a clinical trials for Pfizer‘s Oxbryta (voxelotor) continue to show successful results in pediatric patients. Approved for treating SCD, the oral medication prevents red blood cells from sickle-shaping and breaking down – with data from 10 pediatric trial patients showing that the medication improves red blood cell functionality, and potentially increases oxygen delivery to tissues. These positive results represent a major step forward in managing this debilitating condition more effectively.

OxyDial fully supports the Pfizer initiative and the successful HOPE-KIDS 1 trial, and will be following this ongoing trial closely. We are eager to see more solutions that can help improve the quality of life for those suffering from sickle cell disease worldwide.